Akademik Veri Yönetim Sistemi
ANNALES D ENDOCRINOLOGIE, cilt.86, sa.2, 2025 (SCI-Expanded)
Aim: Co-existing primary aldosteronism (PA) and autonomous cortisol secretion (ACS) has been recently recognized as a distinct entity. This study aimed to assess the incidence of ACS in patients with PA, and its impact on clinical and laboratory parameters. Methods: Ninety-two patients diagnosed with PA were included. Demographic data, comorbidities, laboratory and imaging results were retrospectively analyzed. Patients with overnight 1mg dexamethasone suppression test>1.8 mu g/dL were classified as PA with ACS. Results: Twenty-four patients (26.1%) were in the PA-with-ACS group, and 68 (73.9%) in the PA-without-ACS group. Mean age (P=0.034), body mass index (P=0.034), number of female patients (P=0.012) and maximum adenoma diameter (P<0.001) were higher in the PA-with-ACS group than in the PA-without-ACS group. Basal (P=0.001) and post-saline infusion plasma aldosterone concentrations (PAC) (P=0.009) were higher in the PA-without-ACS group than in the PA-with-ACS group. No significant differences between groups were found in intensity of antihypertensive treatment, presence of type 2 diabetes, coronary artery disease, proteinuria or glomerular filtration rate (P>0.05). Left ventricular hypertrophy (LVH) was detected in 49.4% of patients. Logistic regression demonstrated that PAC and gender were associated factors for LVH. Conclusion: Cortisol co-secretion was identified in approximately one-quarter of patients diagnosed with PA. PA patients without ACS had higher PAC than those with co-existing ACS. According to our results, the co-existing ACS may not seem to have a significant negative impact on clinical parameters in patients with PA. (c) 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.